Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Reaffirms Their Buy Rating on Resmed (RMD)

Tipranks - Tipranks - Sat Jan 31, 6:24AM CST

In a report released today, Craig Wong-Pan from RBC Capital maintained a Buy rating on Resmed, with a price target of $314.00.

Claim 50% Off TipRanks Premium

Wong-Pan covers the Healthcare sector, focusing on stocks such as Resmed, Alcidion Group Limited, and CSL. According to TipRanks, Wong-Pan has an average return of -1.1% and a 47.62% success rate on recommended stocks.

In addition to RBC Capital, Resmed also received a Buy from TipRanks – Google’s Google Medical – Instruments and Supplies in a report issued today. However, on the same day, Piper Sandler maintained a Hold rating on Resmed (NYSE: RMD).

See Insiders’ Hot Stocks on TipRanks >>

Based on Resmed’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.42 billion and a net profit of $392.59 million. In comparison, last year the company earned a revenue of $1.28 billion and had a net profit of $344.62 million

Read More on RMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).